Edition:
India

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

6.23USD
20 Apr 2018
Change (% chg)

$0.04 (+0.65%)
Prev Close
$6.19
Open
$6.15
Day's High
$6.41
Day's Low
$6.11
Volume
38,164
Avg. Vol
90,566
52-wk High
$27.77
52-wk Low
$4.93

Select another date:

Thu, Mar 15 2018

BRIEF-Ra Pharmaceuticals Reports Q4 Loss Per Share $0.67

* RA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Ra Pharmaceuticals Says Public Offering Of 8.40 Mln Common Shares Priced At $6.00/Share

* RA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* RA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 1B Pharmacokinetic Study Evaluating Ra101495 Sc In Patients With Renal Impairment

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 1B PHARMACOKINETIC STUDY EVALUATING RA101495 SC IN PATIENTS WITH RENAL IMPAIRMENT Source text for Eikon: Further company coverage:

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS

BRIEF-Ra Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of RA101495 SC

* RA PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF RA101495 SC IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

BRIEF-Ra Pharmaceuticals posts Q3 loss of $0.68 per share

* Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Ra Pharmaceuticals files for mixed shelf offering of up to $250 million

* Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​ Source text: (http://bit.ly/2A6uuro) Further company coverage:

Select another date: